Skip to main content

Table 1 Urine output, free water clearance (CH2O), urinary AQP2 excretion per minute (u-AQP2), urinary sodium excretion (u-Na), and urinary potassium excretion (u-K) during 24-h urine collection in a randomised, placebo-controlled, double-blind, crossover study of 18 ADPKD patients

From: Effect of tolvaptan on renal handling of water and sodium, GFR and central hemodynamics in autosomal dominant polycystic kidney disease during inhibition of the nitric oxide system: a randomized, placebo-controlled, double blind, crossover study

  Before each examination day p (paired t-test)
Placebo Tolvaptan 60 mg
Urine Output (ml/24 h) 2504 ± 518 2446 ± 615 0.57
CH2O (ml/min) −0.22 ± 0.55 −0.19 ± 0.57 0.72
u-AQP2 (ng/min) 1.10 ± 0.26 1.09 ± 0.28 0.88
u-Na (mmol/24 h) 117 ± 34 111 ± 28 0.46
u-K (mmol/24 h) 66 ± 17 65 ± 18 0.77
  1. Values are means with ± SD. Paired t-test was used for comparison between groups